.

Deeper Knowledge, Faster

  • Plan your formulary budget
  • Analyze global market entry opportunities
  • Identify first generic entrants

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Fuji
Teva
Chinese Patent Office
Covington
Fish and Richardson
UBS
Julphar
Novartis
US Army
McKesson

Generated: June 24, 2017

DrugPatentWatch Database Preview

TWINJECT 0.3 Drug Profile

« Back to Dashboard

Which patents cover Twinject 0.3, and when can generic versions of Twinject 0.3 launch?

Twinject 0.3 is a drug marketed by Amedra Pharms and is included in one NDA. There are two patents protecting this drug.

This drug has forty-three patent family members in fifteen countries.

The generic ingredient in TWINJECT 0.3 is epinephrine. There are nineteen drug master file entries for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the epinephrine profile page.

Summary for Tradename: TWINJECT 0.3

Patents:2
Applicants:1
NDAs:1
Suppliers / Packagers: see list8
Bulk Api Vendors: see list54
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:TWINJECT 0.3 at DailyMed

Pharmacology for Tradename: TWINJECT 0.3

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Amedra Pharms
TWINJECT 0.3
epinephrine
INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS020800-001May 30, 2003DISCNNoNo7,621,891► SubscribeY ► Subscribe
Amedra Pharms
TWINJECT 0.3
epinephrine
INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS020800-001May 30, 2003DISCNNoNo7,297,136► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: TWINJECT 0.3

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,187,224Methods performed by medicine injection apparatuses► Subscribe
7,905,352Kits containing medicine injection devices and containers► Subscribe
7,931,618Apparatuses and methods for injecting medicines to a desired depth► Subscribe
7,927,303Medicine injection devices and methods► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: TWINJECT 0.3

Country Document Number Estimated Expiration
Canada2589899► Subscribe
Norway20080672► Subscribe
European Patent Office1904145► Subscribe
European Patent Office1848490► Subscribe
China101850143► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

QuintilesIMS
Dow
Harvard Business School
Cerilliant
Moodys
Novartis
Colorcon
Federal Trade Commission
Cipla
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot